Jinghua Pharmaceutical Group Co., Ltd.

Shenzhen Stock Exchange 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd. Free Cash Flow for the year ending December 31, 2023: USD 37.03 M

Jinghua Pharmaceutical Group Co., Ltd. Free Cash Flow is USD 37.03 M for the year ending December 31, 2023, a -13.89% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Jinghua Pharmaceutical Group Co., Ltd. Free Cash Flow for the year ending December 31, 2022 was USD 43.01 M, a 21.45% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Free Cash Flow for the year ending December 31, 2021 was USD 35.41 M, a 10.21% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Free Cash Flow for the year ending December 31, 2020 was USD 32.13 M, a 645.05% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Free Cash Flow for the year ending December 31, 2019 was USD 4.31 M, a 138.62% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shenzhen Stock Exchange: 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd.

CEO	Mr. Yunzhong Zhou
IPO Date	Feb. 3, 2010
Location	China
Headquarters	No 2-02#, Xrd Between 3 Haibin Rd & 2 To
Employees	1,493
Sector	Health Care
Industries Pharmaceuticals Petrochemicals

Description

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Nantong, China.

Key trends

Past 5 years